Theriva Biologics, Inc. (TOVX)
TOVXAMEXBiotechnology: Pharmaceutical Preparations
$0.1475
-0.0095 (-6.05%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $6.55m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1360 to $0.4920
- Average volume
- –
- Previous close
- $0.1570
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | $300.0k | – |
| Gross profit | – | – | $300.0k | – |
| Operating income | -$4.44m | -$2.06m | -$2.13m | -$3.29m |
| Net income | -$4.36m | -$2.00m | -$2.04m | -$3.22m |
News
8 latest- Theriva Biologics, Inc. Reports Third Quarter 2026 Results and SYN-004 Asset SaleFintel · 2 days ago
- Theriva Biologics, Inc. Q3 Loss Drops RTTNews · 3 days ago
- Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock Up RTTNews · Nov 3, 2026
- Theriva Biologics Consensus Price Target Raised 60% to $4.08Fintel · Nov 2, 2026
- Theriva Biologics Advances VCN-01 Program; VIRAGE2 Trial Underway In Pancreatic Cancer RTTNews · Aug 11, 2026
- Theriva Doses First Patient With VCN-01 In Phase 2a Trial For Pancreatic Cancer RTTNews · Aug 7, 2026
- Theriva Biologics Advances VIRAGE2 Trial To Refine VCN-01 Dosing In Pancreatic Cancer RTTNews · Jul 8, 2026
- Theriva Gets AEMPS Approval For VIRAGE2 Phase 2a Trial Of VCN-01 In Metastatic PDAC; But Stock Down RTTNews · Jul 7, 2026
The company
Theriva Biologics (NYSE American: TOVX) is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company's subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- North America
- Website
- therivabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.